» Articles » PMID: 15814982

Dynamic Range of Hepatitis C Virus RNA Quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor V2.0 Assay

Overview
Specialty Microbiology
Date 2005 Apr 9
PMID 15814982
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Accurate quantification of hepatitis C virus (HCV) RNA is needed in clinical practice to decide whether to continue or stop pegylated interferon-alpha-ribavirin combination therapy at week 12 of treatment for patients with chronic hepatitis C. Currently the HCV RNA quantification assay most widely used worldwide is the Amplicor HCV Monitor v2.0 assay (Roche Molecular Systems, Pleasanton, Calif.). The HCV RNA extraction step can be automated in the Cobas Ampliprep device. In this work, we show that the dynamic range of HCV RNA quantification of the Cobas Ampliprep/Cobas Amplicor HCV Monitor v2.0 procedure is 600 to 200,000 HCV RNA IU/ml (2.8 to 5.3 log IU/ml), which does not cover the full range of HCV RNA levels in infected patients. Any sample containing more than 200,000 IU/ml (5.3 log IU/ml) must thus be retested after dilution for accurate quantification. These results emphasize the need for commercial HCV RNA quantification assays with a broader range of linear quantification, such as real-time PCR-based assays.

Citing Articles

The association between serum vitamin A concentrations and virus hepatitis among U.S. adults from the NHANES database: a cross-sectional study.

Liu M, Fu J, Zhang X, Fu Q, Ji Y, Chen S Front Nutr. 2024; 11:1387461.

PMID: 39149555 PMC: 11324588. DOI: 10.3389/fnut.2024.1387461.


Seropositive for hepatitis B and C viruses is associated with the risk of decreased bone mineral density in adults: An analysis of studies from the NHANES database.

Tao J, Yan Z, Huang W, Feng T Front Med (Lausanne). 2023; 10:1120083.

PMID: 37035336 PMC: 10073499. DOI: 10.3389/fmed.2023.1120083.


Virus detection using nanoparticles and deep neural network-enabled smartphone system.

Draz M, Vasan A, Muthupandian A, Kanakasabapathy M, Thirumalaraju P, Sreeram A Sci Adv. 2020; 6(51).

PMID: 33328239 PMC: 7744080. DOI: 10.1126/sciadv.abd5354.


Sample-to-Answer Droplet Magnetofluidic Platform for Point-of-Care Hepatitis C Viral Load Quantitation.

Shin D, Trick A, Hsieh Y, Thomas D, Wang T Sci Rep. 2018; 8(1):9793.

PMID: 29955160 PMC: 6023859. DOI: 10.1038/s41598-018-28124-3.


Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection.

Moosavy S, Davoodian P, Nazarnezhad M, Nejatizaheh A, Eftekhar E, Mahboobi H Electron Physician. 2017; 9(10):5646-5656.

PMID: 29238510 PMC: 5718874. DOI: 10.19082/5646.


References
1.
Lee S, Antony A, Lee N, Leibow J, Yang J, Soviero S . Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol. 2000; 38(11):4171-9. PMC: 87559. DOI: 10.1128/JCM.38.11.4171-4179.2000. View

2.
Enomoto M, Nishiguchi S, Shiomi S, Tanaka M, Fukuda K, Ueda T . Comparison of real-time quantitative polymerase chain reaction with three other assays for quantitation of hepatitis C virus. J Gastroenterol Hepatol. 2001; 16(8):904-9. DOI: 10.1046/j.1440-1746.2001.02542.x. View

3.
Pawlotsky J . Molecular diagnosis of viral hepatitis. Gastroenterology. 2002; 122(6):1554-68. DOI: 10.1053/gast.2002.33428. View

4.
Pawlotsky J . Use and interpretation of virological tests for hepatitis C. Hepatology. 2002; 36(5 Suppl 1):S65-73. DOI: 10.1053/jhep.2002.36815. View

5.
Pawlotsky J, McHutchison J . Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. Hepatology. 2004; 39(2):554-67. DOI: 10.1002/hep.20065. View